EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-term drug persistence and clinical outcomes of ustekinumab in Crohn’s disease: a multicenter real-world study from the Hokkaido phoenix cohort

Takahiro Ito iD, Atsuo Maemoto, Nobuhiro Ueno iD, Mikihiro Fujiya iD, Toshifumi Ashida, Daisuke Hirayama iD, Yoshihiro Yokoyama iD, Satoshi Motoya, Masanao Nasuno, Hiroki Tanaka, Takehiko Katsurada iD, Hiroshi Nakase iD

Crohn’s & Colitis 360 · 22.04.2026 · 8 (2)

DOI: 10.1093/crocol/otag059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Crohn’s & Colitis 360, online erschienen am 19.06.2026. Verfasst von Takahiro Ito und 11 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Bowel Disease Center, Sapporo Higashi Tokushukai Hospital, Sapporo, 065-0033, Japan. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although ustekinumab (UST) is effective in Crohn’s disease (CD), long-term real-world data beyond 5 years and its effects on extraintestinal manifestations remain limited. We evaluated UST’s long-term effectiveness and safety in CD.

Methods

This multicenter retrospective study enrolled 317 CD patients who initiated UST between May 2017 and February 2023 at seven institutions in Japan. The primary outcome was the UST continuation rate. The secondary outcomes included factors affecting the continuation rates, surgery-free survival, endoscopic remission rates, improvement in perianal and extraintestinal manifestations, and adverse events.

Results

UST continuation rates at 1, 3, and 5 years were 87.6%, 69.6%, and 66.8%, respectively, with 43 patients followed beyond 5 years (maximum 6.1 years). Multivariate analysis identified week-8 albumin ≥3.3 g/dL (HR 0.30; 95% CI, 0.12-0.72; P = .007) and week-8 C-reactive protein (CRP) ≥0.33 mg/dL (HR 2.05; 95% CI, 1.14-3.69; P = .016) as independent predictors of continuation. Endoscopic remission rates improved significantly from baseline (10%) to week 52 (19%, P < .01) and week 104 (30%, P < .01). Among perianal fistula cases (n = 60), 28% achieved clinical fistula remission and 37% showed improvement. Resolution or improvement was observed in 76% of arthritis and 86% of psoriasis-like lesion cases. The surgery-free survival rate at 5 years was 85.1%. The adverse event rate was 10.7%.

Conclusions

UST demonstrated favorable medium- to long-term effectiveness and safety in CD patients with limited follow-up data beyond 5 years. Week-8 albumin and CRP levels may serve as early predictive biomarkers but require external validation in independent cohorts.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseasedrug persistencelong-term effectivenessustekinumab

Autor:innen und Institutionen

  • Inflammatory Bowel Disease Center, Sapporo Higashi Tokushukai Hospital, Sapporo, 065-0033, Japan.
  • Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, 078-8510, Japan.
  • Inflammatory Bowel Disease Center, Sapporo Tokushukai Hospital, Sapporo, 004-0041, Japan.
  • Inflammatory Bowel Disease Center, Hakodate Goryoukaku Hospital, Hakodate, 040-8611, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, 060-8556, Japan.
  • IBD Center, Sapporo Kosei General Hospital, Sapporo, 060-0033, Japan.

ORCID-Profile: Takahiro Ito, Nobuhiro Ueno, Mikihiro Fujiya, Daisuke Hirayama, Yoshihiro Yokoyama, Takehiko Katsurada, Hiroshi Nakase

Zitieren

APA

Ito, T., Maemoto, A., Ueno, N., Fujiya, M., Ashida, T., Hirayama, D., Yokoyama, Y., Motoya, S., Nasuno, M., Tanaka, H., Katsurada, T., & Nakase, H. (2026). Long-term drug persistence and clinical outcomes of ustekinumab in Crohn’s disease: a multicenter real-world study from the Hokkaido phoenix cohort. Crohn’s & Colitis 360, 8(2). https://doi.org/10.1093/crocol/otag059

Vancouver

Ito T, Maemoto A, Ueno N, Fujiya M, Ashida T, Hirayama D, et al. Long-term drug persistence and clinical outcomes of ustekinumab in Crohn’s disease: a multicenter real-world study from the Hokkaido phoenix cohort. Crohn’s & Colitis 360. 2026;8(2). doi:10.1093/crocol/otag059

BibTeX
@article{Ito2026,
  author = {Ito, Takahiro and Maemoto, Atsuo and Ueno, Nobuhiro and Fujiya, Mikihiro and Ashida, Toshifumi and Hirayama, Daisuke and Yokoyama, Yoshihiro and Motoya, Satoshi and Nasuno, Masanao and Tanaka, Hiroki and Katsurada, Takehiko and Nakase, Hiroshi},
  title = {Long-term drug persistence and clinical outcomes of ustekinumab in Crohn’s disease: a multicenter real-world study from the Hokkaido phoenix cohort},
  journal = {Crohn’s & Colitis 360},
  year = {2026},
  volume = {8},
  number = {2},
  doi = {10.1093/crocol/otag059}
}
Kostenlos starten →